These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Immunomodulation by an inhibitor of S-adenosyl-L-homocysteine hydrolase: inhibition of in vitro and in vivo allogeneic responses.
    Author: Wolos JA, Frondorf KA, Babcock GF, Stripp SA, Bowlin TL.
    Journal: Cell Immunol; 1993 Jul; 149(2):402-8. PubMed ID: 8330316.
    Abstract:
    The response of murine T cells to MHC class II determinants on allogeneic cells induces helper T cell activation and the development of cytotoxic T cells. We have recently established that an S-adenosyl-L-homocysteine hydrolase inhibitor, (Z)-5'-fluoro-4',5'-didehydro-5'-deoxyadenosine (MDL 28,842), is a potent immunosuppressive agent which selectively inhibits T cell activation. In this report we characterize the effect of MDL 28,842 on in vitro and in vivo models of transplant rejection. In vitro, MDL 28,842 inhibited the generation of cytotoxic T cells in the murine mixed lymphocyte reaction with an IC50 of less than 0.1 microM. MDL 28,842 (1.0 microM) totally inhibited the generation of cytotoxic T cells when added up to 3 days after the initiation of culture with no apparent cell toxicity. In vivo, MDL 28,842 given by gavage at 5.0, 2.5, or 1.0 mg/kg/day inhibited the increase in popliteal lymph node weight induced by injection of allogeneic spleen cells into the footpad. MDL 28,842 was also evaluated in a model of graft rejection. Skin allografts on animals given MDL 28,842 at 5 mg/kg/day (ip) for the first 6 days following transplantation survived for 12.2 days, compared to 8.7 days for control animals. Cyclosporin A (CSA) given at 5.0 mg/kg/day did not prolong graft survival. The combination of MDL 28,842 and CSA was not any more effective than MDL 28,842 alone. Based on these findings, we suggest that MDL 28,842 is useful in the prevention of allograft rejection.
    [Abstract] [Full Text] [Related] [New Search]